DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: OCREVUS (ocrelizumab)
       *****************************************************
       #Post#: 2712--------------------------------------------------
       Ocrelizumab and liver injury research information (PubMed)
       By: agate Date: November 4, 2019, 6:43 pm
       ---------------------------------------------------------
       The Overview section of the report on Ocrevus that is part of a
       larger report entitled  LiverTox: Clinical and Research
       Information on Drug-Induced Liver Injury, issued by the National
       Institute of Diabetes and Digestive and Kidney Diseases. This
       section was last updated in July 2018.[font=arial]
  HTML https://www.ncbi.nlm.nih.gov/books/NBK548145/#Ocrelizumab.OVERVIEW[/font]
       The "likelihood score" for Ocrevus is E*, which is defined as:
       [quote][font=comic sans ms]Category E*.[/font] The drug is
       suspected to be capable of causing liver injury or idiosyncratic
       acute liver injury but there have been no convincing cases in
       the medical literature. In some situations cases of acute liver
       injury have been reported to regulatory agencies or mentioned in
       large clinical studies of the drug, but the specifics and
       details supportive of causality assessment are not available.
       The agent is unproven, but suspected to cause liver
       injury.[/quote]
       *****************************************************